🔬 Journal Club: antimicrobial R&D
From AI-driven antibiotic discovery to pivotal clinical trials, this session explored research shaping the future of infection treatment.
🔗🎥 Watch: revive.gardp.org/journal-club...
#DrugDevelopment #REVIVE #AMR
🦠 Clostridioides difficile: prevention, treatment & R&D
With the Peggy Lillis Foundation, experts unpacked the global burden of C. difficile, gaps in surveillance and the challenge of recurrence.
🔗🎥: revive.gardp.org/current-deve...
#AMR #CDiff
Busy Q1 for the #REVIVE team
🧵👇Three webinars tackling some of the most pressing challenges in antimicrobial R&D.
🫁 Cystic fibrosis & chronic lung infections
With the CF AMR Syndicate, this session explored why we need antimicrobials designed for the CF airway.
🔗🎥: revive.gardp.org/chronic-lung...
👋Closing out #ESCMIDGlobal
Grateful for the many conversations over the past few days.
🙏 Thank you to everyone who joined us at the booth and poster sessions. Your questions and perspectives are what make these spaces meaningful.
@escmid.bsky.social
Not every health system has the same tools. So why should AMR and sepsis strategies look the same everywhere?
That's the question at the centre of Session 7 at the 6th #WorldSepsisCongress, moderated by GARDP's Justin Green.
🔗Join us online: www.youtube.com/live/KjawL3C...
📅23 April |🕣08:30 CEST
Just presented at #ESCMIDGlobal
Across 29 gonorrhoea studies in Cambodia, Thailand, Vietnam and South Africa, only 4 include susceptibility data. NAAT-based diagnostics dominate, limiting resistance tracking. Significant surveillance gaps remain.
🤝 Still at Booth G71, come say hi to us!
⌛Today marks the end of the exhibition at #ESCMID2026
If you're still around, we're at Booth G71 — we'd love to connect before the week closes.
Missed #ACC2026?
All sessions are now available to watch.
They cover how antibacterial R&D moves from early research to development, and where the gaps are.
▶️Watch here: acc-conference.com#agenda
Presenting our last poster at #ESCMIDGlobal today.
📍12:00–13:30, Poster Hall B3
Our poster looks at surveillance gaps in gonorrhoea across Cambodia, Thailand, Vietnam and South Africa — from missing regional data to limited resistance insights driven by diagnostic choices.
🧪📊 We just presented at #ESCMIDGlobal.
Carbapenem-resistant Klebsiella pneumoniae in South Africa isn't a single strain story. We're seeing OXA-48-like enzymes, growing NDM presence and resistance to common treatments, making clinical decisions increasingly difficult.
📄 Presenting today at 17:30 in Arena 3 at #ESCMIDGlobal.
Our poster looks at carbapenem-resistant Klebsiella pneumoniae in South Africa where the resistance landscape is far more diverse and complex than a single strain story.
Just presented at #ESCMIDGlobal!
STI guidelines in South Africa are widely followed, but consistent delivery is shaped by workflow and stock realities. Improving guidelines isn't always the main challenge, implementation is. Strong support for new oral gonorrhoea treatments too.
🤝 Visit Booth G71
📄 We're presenting our first poster at #ESCMIDGlobal.
📍Poster Hall B3
Our South Africa work looks at how STI guidelines translate into practice and what shapes uptake on the ground. We're also exploring attitudes toward a new oral gonorrhoea treatment.
If you’re at the conference, join us!
A lot will be shared at #ESCMIDGlobal.
But some of the most important conversations happen between sessions.
🔴🪧 We’re at Booth G71 if you want to connect with our team.
@escmid.bsky.social
🔴 We’re live at #ESCMIDGlobal 2026
Munich is now home to five days of conversations on AMR, infectious diseases, clinical microbiology and what comes next.
Meet the team at Booth G71👋
@escmid.bsky.social
This MoU will focus on sharing expertise to expand availability of this combination antibiotic in LMICs for drug-resistant infections through new access approaches
#AMR #GlobalHealth #AccessToMedicines
🤝 MSD and GARDP have signed a MoU to explore pathways for sustainable access to ceftolozane–tazobactam for the treatment of carbapenem-resistant Pseudomonas aeruginosa (CRPA).
Don't miss out on all the exciting research presented by your colleagues in the Poster Area in Hall B3! Poster sessions are everyday, Sat - Tues, 12:00-13:30 CEST.
Poster Walkthrough sessions directly follow Sat - Mon, 13:30-14:30 CEST. See you there!
https://ow.ly/FtWM50YI4S5
In partnership with Komfo Anokye Teaching Hospital, KCCR, GHID-KCCR and KNUST, and global collaborators including @ucl.ac.uk , @citystgeorges.bsky.social and @pentafoundation.bsky.social, we’re working to improve treatments for neonatal sepsis.
💻Join our #REVIVE webinar on natural product-inspired discovery exploring how approaches like symbiosis & metagenomics are pushing the boundaries of AMR research.
Hear from experts + live Q&A
📅 28 April | ⏰ 09:30–11:00 CEST
🔗https://gotowebinar.pulse.ly/skkvdipmag
@cbeemelmanns.bsky.social
Our REVIVE team will also be at #ESCMIDGlobal. REVIVE supports the antimicrobial R&D community by connecting researchers with experienced antibiotic developers and creating spaces for learning and knowledge exchange.
If you’re working in this space, come meet the team at our Booth G71!
We’ll be at #ESCMIDGlobal this April ✈️
If you’re in Munich, stop by Booth G71, attend our poster presentations and meet the GARDP team working across antibiotic R&D and access.
📅17–21 April | Munich
@escmid.bsky.social
The episode highlights key #AMR developments, including GARDP projects:
• zoliflodacin, a first-in-class oral antibiotic for uncomplicated urogenital gonorrhoea recently approved by the US FDA
• BWC0977, a novel broad-spectrum antibiotic candidate.
#AMR #Antibiotics #BBCPodcast
🔊 “Superbugs: Resistance Rising Part 3,” a new BBC World Service Discovery episode, features GARDP’s Seamus O’Brien and Bugworks’s Anand Anandkumar
🎧 Listen to the full episode: www.bbc.co.uk/programmes/w...
@carb-x.bsky.social I KfW I @bmz.de I @euinemergencies.ec.europa.eu
🌍GARDP at #OneHealthSummit
AMR was highlighted as a growing global threat, with a push to move from commitments to implementation across stewardship & access.
👏We thank the French Government leadership in bringing #AMR to the G7 presidency forefront through this summit.
🔗Communiqué: bit.ly/41Z9kJQ
@ec.europa.eu DG HERA announced a €30 million investment managed by KfW, Germany’s Development Bank, to CARB-X and @gardp.bsky.social to strengthen the global response to AMR. CARB-X will fund early antibacterial research, while GARDP will advance clinical development. #IDSky 🧪
🔗 bit.ly/4v5K81M
@carb-x.bsky.social I KfW I @bmz.de I @euinemergencies.ec.europa.eu
🙌DG HERA announces €30M for CARB-X & GARDP, to be managed by KfW, Germany’s Development Bank.
🔬This new investment will be strengthening early #AMR research to late-stage clinical development.
🌍 A stronger drug development pipeline means better access to lifesaving treatments.
🔗 bit.ly/4so6KrR
